INTRODUCTION
============

Chromosomal translocations that create fusion oncogenes have long been recognized as a cause of human cancers such as leukemias and sarcomas ([@b36-0050095]), and recently have been described in prostate ([@b55-0050095]; [@b8-0050095]) and lung cancer ([@b49-0050095]). Drugs that target oncogenic fusions have also led to dramatic improvements in the treatment of certain cancers ([@b14-0050095]). In Ewing's sarcoma, a malignant bone tumor that most commonly occurs in adolescents and young adults, the discovery of a characteristic chromosomal translocation t(11;22)(q24;q12) ([@b12-0050095]) marked a turning point in the understanding of the biology of the disease. In the majority of Ewing's tumors, the N-terminal portion of EWS becomes fused to the C-terminal portion of FLI-1, which includes an ETS family DNA binding domain ([@b12-0050095]). In some (∼15%) Ewing's tumors, alternative chromosomal translocations create fusions between EWS and other ETS family transcription factors. These alternative fusions suggest that EWS mediates a critical change in ETS family transcription factors that allows them to function aberrantly and promote tumor development, possibly through incorrect regulation of target gene expression.

Ewing's sarcoma is classified as a small-round-blue-cell tumor (SRBCT), a group that also includes medulloblastoma, undifferentiated neuroblastoma, alveolar rhabdomyosarcoma and some types of leukemia. The histology of tumors in this family is that of poorly differentiated cells, scant cytoplasm and round nuclei that stain darkly with hematoxylin. Ewing's sarcomas are frequently associated with bone; however, they can also be found in other tissues, obscuring the identification of a definite cell of origin.

The discovery of EWS-ETS translocations in Ewing's sarcoma family tumors (ESFTs) creates an opportunity for the development of targeted therapy of Ewing's sarcoma, either through direct inhibition of EWS-FLI1, or through the discovery of critical downstream effectors that might themselves be candidates for targeted therapy ([@b57-0050095]; [@b16-0050095]). EWS-FLI1 is believed to function primarily as an aberrant transcription factor. Although microarray studies have identified a large number of potential EWS-FLI1 targets, they have also revealed a few overlapping genes that are consistently regulated by EWS-FLI1 across these varying cellular backgrounds ([@b40-0050095]; [@b50-0050095]; [@b4-0050095]; [@b48-0050095]; [@b19-0050095]). These studies have also indicated that neural genes are frequently induced by EWS-FLI1 ([@b21-0050095]; [@b47-0050095]). In fact, a neuronally expressed homeobox transcription factor, NKX2.2, is required for EWS-FLI1-induced transformation and tumorigenesis in a mouse xenograft model ([@b48-0050095]).

Cell culture experiments have demonstrated that heterologous expression of EWS-FLI1 is toxic to many cell types by inducing growth arrest or apoptosis ([@b13-0050095]; [@b33-0050095]). These observations, along with the relative lack of differentiation in Ewing's tumor cells, have led to the hypothesis that only a subset of undifferentiated precursor cell is capable of responding to EWS-FLI1 to generate Ewing's sarcoma. Mouse mesenchymal progenitor cells are one type of cell that tolerates EWS-FLI1 expression and generate Ewing's-like tumors when transplanted into mice ([@b44-0050095]). Although this result is a promising step toward understanding the possible origins of Ewing's sarcoma, mesenchymal progenitor cells remain relatively uncharacterized at a molecular level, therefore the cellular context required for EWS-FLI1 to exert its function remains unknown. Thus, the molecular characteristics that are required for EWS-FLI1 responsiveness, as well as the downstream mechanisms by which EWS-FLI1 gives rise to tumors, remain to be elucidated.

Several mouse models of EWS-FLI1 transgenic expression have been reported. Expression of EWS-FLI1 in hematopoietic tissues in an *Mx1-Cre* conditional mouse model induced myeloid or erythroid leukemia in transgenic mice ([@b56-0050095]). Recently, *EWS-FLI1* was conditionally expressed in mice under the control of a primitive mesenchymal cell promoter, resulting in limb defects and accelerated development of undifferentiated sarcoma when introduced into the p53 mutant background ([@b35-0050095]). Further studies in which EWS-FLI1 is expressed in a different cell type or at a specific developmental stage are required to more fully recapitulate Ewing's sarcoma in the mouse.

Models of several types of cancers have recently been developed in the zebrafish *Danio rerio*, including melanoma, leukemia and rhabdomyosarcoma ([@b1-0050095]). Here, we report that expression of human EWS-FLI1 in zebrafish causes tumors strongly resembling human Ewing's sarcoma. We identify an *EWS-FLI1* gene expression signature in the zebrafish tumors, which reveals striking conservation of key EWS-FLI1 targets between fish and human Ewing's tumors. Additionally, we show that EWS-FLI1 exerts powerful effects on embryonic development, indicating that EWS-FLI1 functions through conserved developmental signaling pathways.

RESULTS
=======

Expression of a human EWS-FLI1 transgene causes small-round-blue-cell tumors in zebrafish
-----------------------------------------------------------------------------------------

The molecular basis of Ewing's sarcoma is unknown despite the strong association with the EWS-FLI1 oncogene. To develop an animal model in which to study the function of EWS-FLI1, we created transgenic zebrafish carrying the human EWS-FLI1 fusion protein, using the Tol2 transposon system ([@b28-0050095]). Three different transgenes were generated, two of which use the zebrafish heat-shock (*hsp70*) promoter, and another using the β-actin promoter, to drive expression of a FLAG-tagged human *EWS-FLI1* ([Fig. 1A](#f1-0050095){ref-type="fig"}).

From over 300 wild-type embryos injected with the three different *EWS-FLI1* transgenes and raised to adulthood, we identified two fish with tumors. One of the fish was identified by the appearance of outgrowths covering the head at 15 months of age. Sectioning and staining revealed the presence of diffuse tumor cells covering the surface of the head, as well as within the head, gills, and body cavity ([Table 1](#t1-0050095){ref-type="table"}; [Fig. 1C,D](#f1-0050095){ref-type="fig"}). This histology resembles that of existing zebrafish models of leukemia ([@b30-0050095]; [@b9-0050095]). The other tumor identified in a wild-type fish was a solid tumor that arose in proximity to the eye at 12 months of age ([Table 1](#t1-0050095){ref-type="table"}; [Fig. 1E,F](#f1-0050095){ref-type="fig"}). Both of these histologies are consistent with the SRBCT morphological category. These tumor types rarely occur spontaneously in zebrafish ([@b2-0050095]). The identification of zebrafish tumors that histologically resemble Ewing's family tumors was encouraging, but the low incidence of tumors precluded the analysis of a large number of tumors.

Because we observed a low incidence of tumors, we suspected that cellular tumor suppressive mechanisms might be inhibiting tumor development in the wild-type zebrafish. We identified the p53 pathway as a likely candidate for such tumor suppression. Mutations in *tp53* occur in a subset of primary Ewing's tumors ([@b18-0050095]; [@b24-0050095]) and research suggests that EWS-FLI1 can induce a p53-dependent growth arrest ([@b33-0050095]). Additionally, mutation of *tp53* has been shown to be a sensitized background for the development of other tumors in the zebrafish, including rhabdomyosarcoma and melanoma models ([@b43-0050095]; [@b31-0050095]), as well as in a mouse model of EWS-FLI1-driven tumor development ([@b35-0050095]). Zebrafish with a mutation in *tp53* are predisposed to develop malignant peripheral nerve sheath tumors (MPNSTs) ([@b7-0050095]), composed of spindle cells with abundant cytoplasm. Based on the histology of the two tumors we identified in wild-type *EWS-FLI1* transgenic fish, we anticipated that the histology of a tumor driven by EWS-FLI1 would be distinct from this tumor type. Therefore, we injected the *EWS-FLI1* transposons into p53-deficient zebrafish embryos and raised these fish to adulthood.

From 6 to 19 months of age, we identified 48 tumors from approximately 150 *tp53* mutant zebrafish injected with one of the three EWS-FLI1 transposons ([Table 1](#t1-0050095){ref-type="table"}). Of these, 33 were classified based on their histology as malignant peripheral nerve sheath tumors (MPNSTs). Diffuse, leukemia-like tumors were identified in four fish ([Fig. 1G](#f1-0050095){ref-type="fig"}). The remaining ten tumors exhibited SRBCT histology, but were not diffuse and instead presented as solid tumor masses ([Fig. 1H](#f1-0050095){ref-type="fig"}). The identification of both solid and diffuse tumors suggests that EWS-FLI1 can induce the formation of at least two tumor types in the zebrafish. Both MPNSTs and SRBCTs were identified at similar ages of onset (average age at sacrifice 13.1 months each). The small round blue cell morphology was not identified in any tumors occurring in uninjected *tp53* mutants. Therefore, this histological phenotype is associated with the presence of EWS-FLI1 and is consistent with the pathology of human Ewing's sarcoma.

To address the similarity of the diffuse tumors to leukemias, we performed quantitative RT-PCR for two genes known to be highly expressed in other zebrafish models of leukemia, *rag2* and *lck* ([@b30-0050095]). Both genes were more highly expressed in RNA from samples classified as leukemia-like tumors (supplementary material Fig. S2). The tumors classified as zebrafish solid SRBCTs did show slightly increased expression of *rag2* and *lck* compared with levels in the wild type but were substantially lower than expression in the leukemia-like tumors. Thus, the expression of two conserved markers for leukemia is consistent with the histological characterization of the leukemia-like tumors identified in zebrafish.

SRBCTs are transplantable
-------------------------

To show that the zebrafish Ewing's sarcomas have malignant potential, we performed transplantation experiments. Following dissection and manual dissociation of two SRBCTs derived from *tp53* mutants, approximately 1 million cells were injected intraperitoneally into irradiated wild-type adult zebrafish. Recently, a number of transplantation experiments have been performed in zebrafish tumor models with transplanted tumors typically developing within 2 to 8 weeks post-transplant \[reviewed by Taylor and Zon ([@b52-0050095])\]. Both of our primary transplants formed new tumors within 3--5 weeks, consistent with these previously reported results. These tumors were then subjected to further rounds of transplantation (supplementary material Table S1). Even when the number of injected tumor cells was reduced more than 10 times (see number of cells transplanted in 1° vs 4° or 8° transplant in supplementary material Table S1), the tumors continued to regenerate. One of the two secondary transplants continued to generate new tumors in each host and was serially transplanted nine times. These successful transplantation experiments indicate that the tumor cells continue to proliferate. Although one tumor (D85) appeared to have diminished capacity to regenerate with subsequent transplants, the second tumor (D86) maintained an average tumor development time of 17 days over eight rounds of transplantation. Both primary tumors were initially categorized as solid SRBCTs based on their histology. The subsequent tumors continued to exhibit similar histology, although some tumor variation was observed ([Fig. 2](#f2-0050095){ref-type="fig"}). After several rounds of transplantation, tumors appeared to have increased cytoplasm in some regions (see 6° and 8° in [Fig. 2B](#f2-0050095){ref-type="fig"}). Both primary tumors were derived from *tp53* mutant fish, but formed new tumors in the recipient wild-type hosts. From these transplantation experiments, we conclude that, although p53 might serve as a barrier to transformation by EWS-FLI1, this effect is probably autonomous to the tumor cell and not dependent on the p53 status of the surrounding normal tissue.

![**EWS-FLI1 induces SRBCTs in zebrafish.** (A) Schematic of Tol2 transposons including the *hsp70* or the *β-actin* promoter, FLAG-tag (black rectangle), human *EWS-FLI1* coding sequence, *IRES-GFP* sequence (gray rectangle), flanked by Tol2 recombination sites (triangles). (B-H) H&E staining of sagittal sections of adult zebrafish. (B) Control adult zebrafish. Wild-type zebrafish injected with EWS-FLI1 developed an invasive leukemia like-tumor (C magnified in D) or a solid small round blue cell tumor of the eye (arrow in E) (E magnified in F). *tp53* mutants injected with *EWS-FLI1* transposons also develop leukemia (G) or solid tumors (H) with similar histology. Scale bars: 200 μm (B,C,E), 50 μm (D,F--H).](DMM007401F1){#f1-0050095}

###### 

Tumor spectrum of EWS-FLI1 transgenic zebrafish
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Zebrafish SRBCTs express the *EWS-FLI1* transgene
-------------------------------------------------

To determine whether the tumors express the *EWS-FLI1* mRNA, we tested for the presence of EWS-FLI1 using RT-PCR. *EWS-FLI1* mRNA was present at detectable levels in four of six of the SRBCT primary or transplanted tumors analyzed (supplementary material Fig. S1 and data not shown). By contrast, only one of ten MPNST tumors exhibited *EWS-FLI1* expression (supplementary material Fig. S1 and data not shown). We conclude that the SRBCTs were caused by the presence of the transgene, but that the MPNSTs were attributable to the mutation in *tp53*. Those tumors for which we were unable to detect *EWS-FLI1* mRNA might have undetectable levels of expression, normal tissue co-isolated with the tumor tissue that obscures detection or might have expressed EWS-FLI1 during tumor initiation but lost expression in later stages of tumor growth. Together, the pathology of these tumors and expression of *EWS-FLI1* mRNA in the majority of tumor samples indicate that these tumors are a model of Ewing's sarcoma in the zebrafish.

Gene expression profiling of zebrafish SRBCTs
---------------------------------------------

The histology of the zebrafish tumors strongly resembles that of Ewing's sarcoma and other human SRBCTs. Based on the model that EWS-FLI1 acts as a transcription factor, we hypothesized that this similarity in cellular morphology was caused by changes in gene expression driven by EWS-FLI1. We isolated tissue from three solid SRBCTs and hybridized the RNA to Affymetrix zebrafish gene expression arrays. The most highly expressed genes in these zebrafish tumors were ribosomal proteins and components of the electron transport chain, consistent with a general requirement for protein translation and energy production in proliferating cells.

Using a mutation in the conserved tumor suppressor p53 as a sensitized genetic background that is likely to affect the expression of many genes that contribute to tumor initiation or development. Although the precise relationship between EWS-FLI1 and p53 remains unknown, we wanted to eliminate those genes with expression affected by the loss of p53. Therefore, to determine those genes that might be regulated more specifically by EWS-FLI1 and not generally overexpressed in tumors, we compared the gene expression profile with three of the MPNSTs that occurred in the *tp53* mutants.

![**H&E staining of selected serially transplanted tumors originating from two different zebrafish SRBCTs.** (A) Tumor D85; (B) tumor D86 (see supplementary material Table S1). Numbers indicate serial transplants (primary, secondary, tertiary etc.).](DMM007401F2){#f2-0050095}

To examine total variation within these samples, we determined the correlation coefficients among the biological replicates (supplementary material Table S2). The MPNST samples were well correlated (mean *R*=0.95). The SRBCT samples had a lower average correlation (mean *R*=0.90), suggesting more variation among samples. Increased variation might be expected from mosaic integration of the transgene and differences in the tissue of origin, because two tumors presented in the abdominal cavity and one tumor presented in the eye.

Comparing these two tumor types revealed 421 probes that were differentially expressed between the SRBCTs and the malignant peripheral nerve sheath tumors ([Fig. 3A,B](#f3-0050095){ref-type="fig"}) (supplementary material Table S3). These probes were annotated to 376 zebrafish genes, which we will refer to as the zebrafish SRBCT up- and downregulated genes. The majority (243 genes) were downregulated in SRBCTs, suggesting repression by EWS-FLI1. Although EWS-FLI1 is predicted to be a transcriptional activator, our finding of a larger proportion of genes with reduced expression in EWS-FLI1-driven tumors is in agreement with gene expression studies in human and mouse systems. These downregulated genes probably reflect indirect effects on gene expression. In fact, the SRBCT upregulated gene set is significantly enriched for genes with predicted roles in transcription: at least 17 genes involved in the regulation of transcription (2.44-fold enrichment, *P*=0.0026) are contained within this set. Therefore, many of the gene expression changes, particularly those genes that are repressed, might be indirect targets of EWS-FLI1 through these transcription factors.

![**Gene expression in zebrafish SRBCTs is distinct from MPNSTs and similar to human** ***EWS-FLI1*** **gene expression data.** (A) Histology of representative zebrafish MPNST (left) and SRBCT (right) that were used for microarray analysis. Scale bars: 50 μm. (B) Heat map of 421 probes that exhibited differential expression between MPNSTs and SRBCTs. Yellow, high expression; blue; low expression. (C) Quantitative RT-PCR of selected SRBCT upregulated genes. (D,E) GSEA using human homologs of zebrafish genes shown in B compared with human gene expression data from (D) stable knockdown of EWS-FLI1 (red, higher expression in A673 Ewing's cell line; blue, higher expression following EWS-FLI1 knockdown in A673 cells) or (E) inducible expression of EWS-FLI1 in a bone-marrow-derived stromal cell line (red, higher expression in EWS-FLI1 expressing cells; blue, higher expression in control cells).](DMM007401F3){#f3-0050095}

Although a specific cell of origin of Ewing's sarcoma has not yet been identified, multiple studies have found that Ewing's sarcoma cells often express genes associated with neural development ([@b50-0050095]; [@b21-0050095]; [@b47-0050095]). Indeed, the zebrafish SRBCT upregulated gene list is enriched for genes involved in nervous system development and neurogenesis (3.87-fold, *P*=0.0024), including *nkx2.2a*, *olig2*, *sox3* and *asc1a/b* (supplementary material Table S3). We performed quantitative RT-PCR to validate higher expression of *nkx2.2* and *olig2* in the zebrafish SRBCTs ([Fig. 3C](#f3-0050095){ref-type="fig"}). The downregulated gene list does not exhibit enrichment in this category, indicating that a neural-associated gene expression profile is correlated with the presence of EWS-FLI1.

To compare these zebrafish tumors to human studies of EWS-FLI1-regulated gene expression, the differentially expressed zebrafish genes were mapped to their human homologs. The zebrafish probes were mapped to 97 human homologs (upregulated in SRBCTs) and 162 human homologs (downregulated). To compare these genes with the combined results from several human studies, we used a gene set generated by a meta-analysis of multiple microarray experiments that identified a core EWS-FLI1 gene expression signature of 503 EWS-FLI1 upregulated genes and 293 EWS-FLI1 downregulated genes ([@b19-0050095]). Comparing the genes from the human upregulated gene signature with the zebrafish SRBCT-enriched genes revealed an overlap of six genes: *NKX2-2*, *MYC*, *MAPT*, *SALL2*, *PADI2* and *POU3F1*. The number of common genes reflects a slight, although not statistically significant, overlap (1.7-fold) between the two gene lists. However, the identity of the overlapping genes suggests that they are biologically relevant. *NKX2-2* is one of very few genes that have been shown to be a critically important downstream target of EWS-FLI1 in tumorigenesis ([@b48-0050095]), and mediates transcriptional repression downstream of EWS-FLI1 ([@b41-0050095]). The oncogene *MYC* has also been previously identified to be upregulated by EWS-FLI1 ([@b11-0050095]; [@b60-0050095]). The microtubule associated protein tau (*MAPT*) and *NKX2-2* were in a group of only ten genes identified in an analysis comparing Ewing's family tumors and cell lines with peripheral blood ([@b10-0050095]).

Comparing gene lists directly might fail to identify those genes with expression that does not meet a certain criteria in some experiments, but do exhibit the same pattern of change in gene expression. Published analyses of expression profiling of EWS-FLI1 models have produced gene sets with very limited overlap. An alternative way to compare expression profiling experiments is to use gene set enrichment analysis (GSEA), which provides a more comprehensive look at the way a candidate gene set behaves in another dataset ([@b38-0050095]; [@b51-0050095]). We used publicly available microarray data from several studies of EWS-FLI1-regulated gene expression in human cell lines or tumors. Three datasets were generated using gene expression profiling following the knockdown of EWS-FLI1 in the Ewing's sarcoma cell lines ([@b48-0050095]; [@b54-0050095]; [@b27-0050095]). In two of the three datasets, one of our gene sets (either up- or downregulated) was significantly enriched ([Table 2](#t2-0050095){ref-type="table"}). An additional dataset generated by inducible expression of *EWS-FLI1* in a bone marrow stromal cell line ([@b37-0050095]) was enriched for the zebrafish upregulated gene set. Thus, at least one zebrafish gene set was in enriched in 3 of 4 datasets testing EWS-FLI1-induced gene expression profiles in cell culture systems.

The datasets used in the above analyses were generated in cell culture systems. To determine whether our data also showed similarity to human Ewing's tumors, we used publicly available gene expression dataset from a panel of 96 human sarcomas which included five Ewing's tumors and four malignant peripheral nerve sheath tumors ([@b20-0050095]). The zebrafish SRBCT upregulated genes were enriched in the Ewing's sarcoma tumor samples ([Table 2](#t2-0050095){ref-type="table"}). Two published datasets compared Ewing's tumors to bone marrow stromal cells, a possible cell of origin for Ewing's sarcoma ([@b54-0050095]; [@b37-0050095]). In both of these datasets, the Ewing's sarcoma samples were enriched for the zebrafish upregulated gene set; the Miyagawa dataset was also enriched for the downregulated gene set ([Table 2](#t2-0050095){ref-type="table"}). Two additional datasets compared Ewing's sarcoma with either neuroblastoma or rhabdomysosarcoma ([@b3-0050095]; [@b50-0050095]) and did not show enrichment of the zebrafish gene sets (data not shown). Taken together with the similar histology of the zebrafish SRBCTs and human Ewing's sarcomas, these data highlight the strong cross-species conservation of cellular and transcriptional responses to EWS-FLI1.

EWS-FLI1 impairs zebrafish embryonic development
------------------------------------------------

The Ewing's-like tumors that we identified in the adult zebrafish were probably derived from a subset of cells because of the mosaic nature of transposon integration. Although all fish were screened by PCR of embryos for germline transmission of the *EWS-FLI1* transgene, no founders were initially identified. Because EWS-FLI1 has a toxic effect on many types of human cells, we hypothesized that it might also be toxic to germ cells or early embryonic cells. Indeed, expression of human or zebrafish versions of EWS-FLI1 by mRNA injection in zebrafish embryos caused abnormal development, mitotic defects and cell death ([@b15-0050095]). Such effects would prevent the identification of stable transgenic lines, as well as preclude further analysis of the effects of EWS-FLI1 on embryonic development. Alternatively, our PCR screening method might not have been robust enough to detect the transgene in pools of embryos, particularly if the rate of transmission was low. To address this possibility, we used a transgenesis marker, *cmlc2:EGFP* that expresses GFP in the heart beginning at about 24 hours post fertilization (h.p.f.). We generated an additional transposon in which the *hsp70* promoter drives expression of EWS-FLI1 and the *cmlc2* promoter drives GFP expression from a separate cassette. Following injection of this transposon, we identified a founder that transmitted progeny with GFP expression in the heart. This transgenic line is denoted Tg(*hsp70:EWS-FLI:IRES-EGFP; clmc2:EGFP*)sw3 and will be referred to as *hsp70:EWS-FLI1* for simplicity.

To determine the effect of transgenic *EWS-FLI1* on embryonic gene expression, we heat shocked the transgenic embryos at 50% epiboly, collected total RNA 4 hours later, and performed microarray analysis (supplementary material Tables S4, S5). There was a modest overlap in genes upregulated in zebrafish SRBCTs and transgenic embryos, or downregulated in the tumors and the transgenic embryos (supplementary material Table S6). This modest overlap is probably due to the fact that the highly dynamic context of a developing embryo, in which many different tissue-specific enhancers and pathways might be active, differs from that of a tumor derived from one particular lineage. In a rapidly developing embryo, indirect effects of EWS-FLI1 expression might in fact predominate, making the comparison with human Ewing's tumors more problematic.

We speculated that the embryonic developmental phenotype of *EWS-FLI1* transgenic embryos might therefore provide a more robust readout of the effects of EWS-FLI1 on conserved signaling pathways that normally function during development. We observed that the GFP-positive transgenic progeny exhibited developmental dysmorphology, including reduced head development and eye size, as well as severe pericardial edema and subsequent lethality ([Fig. 4B](#f4-0050095){ref-type="fig"}). Although ∼90% of the transgenic embryos die, we were able to raise some escapers to adulthood; these survivors exhibited normal development through adulthood. Two subsequent *EWS-FLI1* transgenic lines have been identified with the same phenotype (data not shown). To confirm that these developmental phenotypes were indeed caused by EWS-FLI1, we injected a morpholino oligonucleotide (MO) targeting the *EWS-FLI1* transgene. Injection of this MO suppressed the pericardial edema and developmental defects in the F1 embryos ([Fig. 4C,D](#f4-0050095){ref-type="fig"}). These rescued embryos survived and developed normally to adulthood. Therefore, EWS-FLI1 is responsible for the developmental phenotypes observed in these transgenic embryos and probably acts on developmental signaling pathways to exert these effects.

###### 

Gene-set enrichment analysis of zebrafish SRBCT gene sets in human cells and tumors
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![**EWS-FLI1 induces developmental defects in zebrafish embryos.** (A) Non-transgenic (GFP--) embryos are wild type. (B) Transgenic embryos (GFP+) carrying a heat-shock-inducible *EWS-FLI1* transgene exhibit pericardial edema (arrow) and reduced head and eye size. (C) A morpholino against the transgene decreases the penetrance of the pericardial edema phenotype. (D) Percentage of transgenic embryos exhibiting pericardial edema is decreased using a morpholino targeting the *EWS-FLI1* transgene. (E) RT-PCR for *EWS-FLI1* shows low level of expression without heat shock (--HS) and increased expression following heat shock (+HS). no RT, no RT negative control.](DMM007401F4){#f4-0050095}

The heat-shock promoter used to express EWS-FLI1 can exhibit basal transcriptional activity. We tested whether EWS-FLI1 was expressed in these embryos in the presence and absence of heat shock. RT-PCR of RNA from GFP-positive F1 embryos reveals that *EWS-FLI1* is expressed in these embryos even in the absence of heat shock, and also that expression increases following heat shock ([Fig. 4E](#f4-0050095){ref-type="fig"}). We evaluated embryonic development following heat shock at the 50% epiboly stage to determine whether increased *EWS-FLI1* expression would further perturb embryonic development. Consistent with the increase in *EWS-FLI1* gene expression after heat shock, these embryos exhibited more severe developmental defects. Similarly to previous results ([@b15-0050095]), embryonic expression of EWS-FLI1 caused mitotic defects (11/25 mitoses in transgenic embryos exhibited abnormal or monopolar spindles, compared with 1/25 in control embryos; *P*=0.002 by Fisher's exact test) (supplementary material Fig. S3). At 2 days post fertilization, the embryos have a shorter anterior-posterior axis, as well as reduced head development ([Fig. 5A,B](#f5-0050095){ref-type="fig"}). At an earlier stage (18 somites), a reduced anterior-posterior axis is already evident, with extremely reduced tail extension. At this stage, in situ hybridization for *myoD* reveals that the somites are wider (*P*\<0.02) ([Fig. 5C--E](#f5-0050095){ref-type="fig"}). The average angle between the head and the tail is also significantly greater (17.5° vs 60.8°; *P*\<0.001) in the transgenic embryos compared with the control embryos ([Fig. 5C,D,F](#f5-0050095){ref-type="fig"}). Reduced body length and increased somite width are phenotypes that are frequently associated with convergence and extension defects. Convergence and extension movements are controlled largely by the non-canonical Wnt signaling pathway ([@b45-0050095]). Therefore, EWS-FLI1 might be modulating non-canonical Wnt signaling to perturb embryonic development in this zebrafish transgenic line.

DISCUSSION
==========

The identification of human EWS-FLI1-driven tumors in zebrafish shows that critical downstream transcriptional targets and protein interactions that allow EWS-FLI1 to generate tumors are conserved between zebrafish and humans. The developmental phenotypes caused by EWS-FLI1 in zebrafish embryos provides further support for this conservation and provides a second, independent context in which to dissect the downstream targets of EWS-FLI1. Creating regulated or inducible models of *EWS-FLI1* expression will improve this system by allowing us to induce EWS-FLI1 in a temporal or tissue-specific fashion to increase the tumor incidence. A model in which we could reliably produce SRBCTs in the zebrafish would provide an ideal platform for chemical or genetic screening for EWS-FLI1 inhibitors.

The identification of both solid and infiltrating tumors suggests that EWS-FLI1 can induce the formation of both of these tumor types in the zebrafish. Both of these tumor types have also occurred in transgenic mice expressing *EWS-FLI1* using tissue-specific promoters, suggesting that the cellular context in which *EWS-FLI1* is expressed dictates the tumor type that subsequently develops ([@b56-0050095]; [@b35-0050095]). The finding that EWS-FLI1 promotes leukemia in both mouse and zebrafish indicates that this property of EWS-FLI1 is conserved. Although EWS-FLI1-associated leukemia is not observed in humans, a closely related fusion of TLS-ERG is associated with acute myeloid leukemia ([@b25-0050095]). Rare cases of pre-B-cell lymphoblastic leukemia with the *EWS-FLI1* translocation have also been reported ([@b42-0050095]; [@b26-0050095]). These cases suggest a connection between EWS translocation proteins and cancers of the hematopoietic lineage. Differences in cellular context, cellular niche, expression level, or temporal expression in animal models may account for the lack of EWS-FLI1-associated leukemia in humans.

![**EWS-FLI1 affects convergence and extension in zebrafish embryos.** Heat-shocked control (A) and *EWS-FLI1* transgenic (B) embryos at 2 d.p.f. reveals that transgenic embryos are shorter with reduced head development. At the 18 somite stage, in situ hybridization for *myoD* in heat-shocked control (C) and *EWS-FLI1* transgenic (D) reveals a wider somite width (E) and a shorter anterior-posterior axis as measured by the angle between the head and tail (F) in transgenic embryos (\**P*\<0.02, \*\**P*\<0.001; error bars indicate s.e.m.).](DMM007401F5){#f5-0050095}

Serial transplantation of two zebrafish tumors demonstrated the independent growth of the tumor cells. The histological variation observed following several rounds of transplantation could be caused by tumor evolution, stochastic differences in subpopulations of cells transplanted, or differences in signals or environment within the host tissue. Although some rounds of transplantation required a longer time for tumor development, the number of transplant recipients was not large enough to confirm that this difference is statistically significant. Presently, serial transplantation studies performed in zebrafish are becoming a powerful tool to study cancer in this model organism \[reviewed by Taylor and Zon ([@b52-0050095])\]. Most zebrafish cancer models to date have been shown to be serially transplantable; however, some differences are becoming evident; a KRAS-induced MPD was unable to be serially transplanted ([@b32-0050095]) and a T-ALL line showed increasing malignancy with subsequent transplants ([@b17-0050095]). Understanding the mechanisms underlying engraftment and proliferation in zebrafish cancer models might shed light on tumor progression and metastasis in human cancer.

In the zebrafish model, we identified tumors in animals injected with a *hsp70:EWS-FLI1* transgene, even in the absence of heat shock. In these tumors, the heat shock promoter is probably acting as a minimal promoter that allows *EWS-FLI1* expression to be controlled by local enhancers at the genomic site of transgene integration. Under this model, the two different histologies of SRBCTs that we identified might arise because of trapping of different types of tissue-specific enhancers by the *hsp70:EWS-FLI1* transgene. Identification of these enhancers, and the tissue type they define, could perhaps help clarify the Ewing's sarcoma cell of origin.

Mutation of *tp53* provided a sensitized background for the formation of SRBCTs in zebrafish. Although mutations in *tp53* occur in only a subset of Ewing's sarcomas ([@b24-0050095]), the p53 pathway might also be inhibited by other mechanisms ([@b5-0050095]; [@b34-0050095]). Interestingly, the solid SRBCTs that we identified most frequently arose in proximity to the eye and abdomen, the locations in which MPNSTs also develop in *tp53* mutant zebrafish ([@b7-0050095]). This cell type might be predisposed to tumor development in the zebrafish, or the MPNSTs and SRBCTS might both be able to arise from the same type of nerve sheath cell. An alternative possibility is that the tumors originate as a result of the loss of p53, but that the presence of EWS-FLI1 drives the tumor cells to a less differentiated, more primitive state, which results in the SRBCT histology. These possibilities cannot be distinguished from this study.

The microarray analysis provides firm support for the validity of this system as a model of human Ewing's sarcoma. The identification of relevant target genes and the enrichment of the zebrafish gene set in both Ewing's sarcoma cell lines and primary tumors reveal that EWS-FLI1 produces similar gene expression changes in the zebrafish tumors. By comparing the gene expression profiles to MPNSTs, we eliminated those genes that are generally affected in tumors and also those genes that might be changed because of the absence of p53. Therefore, additional gene expression changes caused by EWS-FLI1 might also exist if they share these properties. Our gene set is therefore a conservative estimate of the transcriptional changes caused by EWS-FLI1, but is also more likely to include specific targets and features of Ewing's sarcoma.

We identified some genes that were upregulated in zebrafish SRBCTs but downregulated in human EWS-FLI1-dependent expression datasets, or vice versa. Differences in regulatory elements, protein-protein interactions, cellular niche and growth factors, and many other differences might exist between animal models and humans. Of course, animal models will almost never completely recapitulate the human conditions. In this context, the similarity of these tumors suggests that these differences are not crucial to tumorigenesis. Therefore, the gene expression profile we found is likely to include relevant biological targets downstream of EWS-FLI1. These gene sets also show enrichment in multiple, independent datasets generated from experiments in human cell lines. Even among the various microarray analyses performed from human cell lines, the differences between experiments are much greater than the similarities. A meta-analysis used to generate a EWS-FLI1 core-expression signature concluded that the core was more similar to primary Ewing's sarcoma, than any of the individual experiments ([@b19-0050095]). Therefore, each additional model of Ewing's sarcoma provides new information toward understanding the transcriptional consequences of EWS-FLI1 and, by extension, facilitates the development of improved, targeted therapies of Ewing's sarcoma.

The stable *EWS-FLI1*-expressing transgenic line that we established represents a valuable new tool for the study of EWS-FLI1 cellular function. Many signaling pathways that function in zebrafish embryonic development have been dissected. The phenotypes observed in the *EWS-FLI1* embryos are consistent with defects in convergence and extension during gastrulation. The non-canonical Wnt-PCP and BMP signaling pathways as well as other genes, including those encoding Stat3, heterotrimeric G proteins and cell adhesion molecules contribute to proper convergence and extension in zebrafish embryos ([@b45-0050095]). The convergence and extension defect we observed in transgenic *EWS-FLI1* embryos suggests that EWS-FLI1 directly interferes with genes that function during this process; a finding made possible by the expression of the transgene in the context of a developing embryo, in which the interplay of multiple signaling pathways determines embryo morphology. Future experiments will be required to fully dissect the relationship between EWS-FLI1 and these morphological defects.

The phenotype we observed in the *hsp70:EWS-FLI1* line was not identical to that previously reported following mRNA injection ([@b15-0050095]). Similarly to our analysis, embryos with severe trunk defects, including a shorter axis, were observed, as well as abnormal mitoses. We speculate that mRNA injection results in a higher level of *EWS-FLI1* expression as well as an earlier onset of expression that might account for some of these differences.

This animal model of EWS-FLI1 function is amenable to future pathway and genetic analysis and provides a new approach to dissecting the role of EWS-FLI1. Genes that contribute to cancer frequently have crucial roles in embryonic development; therefore, elucidating the mechanism by which EWS-FLI1 perturbs development will also shed light on its contribution to tumorigenesis. Importantly, these zebrafish models represent the first vertebrate model for EWS-FLI1 function that is amenable to genetic and chemical screening. A system to perform suppressor screens for EWS-FLI1-induced phenotypes in a whole animal context has until now, been elusive. Future genetic and chemical screens for EWS-FLI1 suppressors in the zebrafish should reveal novel downstream effectors and therapeutics for the treatment of Ewing's sarcoma.

METHODS
=======

Zebrafish care, maintenance and mutants
---------------------------------------

Zebrafish were raised according to standard protocols ([@b59-0050095]). For mutation of *tp53*, the allele *TP53^zdf1^* was used ([@b7-0050095]). A morpholino targeting the 5′ end of the *FLAG-EWS-FLI1* mRNA (5′-TGTCATCGTCGTCCTTGTAGTCCAT-3′) was purchased from GeneTools (Philomath, OR). Heat shock of transgenic embryos was performed by incubating embryos at 39°C for 30 minutes at 50% epiboly.

Plasmid construction
--------------------

The plasmid containing a triple-FLAG-tagged human EWS-FLI1 of the type 1 fusion, which fuses codon 265 of EWS to codon 219 of FLI1 was provided by Chris Denny, University of California-Los Angeles, Los Angeles, CA. This plasmid was digested with *Sma*I and *Cla*I and ligated to the plasmid containing the 1.5 kb *hsp70* promoter digested with *Eco*RV and *Cla*I fragment (provided by Jon Kuwada, University of Michigan, Ann Arbor, MI). This plasmid was then digested with *Sme*I and *Cla*I and ligated into pT2KXIG following digestion with *Xho*I and *Cla*I to create pTZ109 (*hsp70:EWS-FLI1*). pTZ109 was digested with *Not*I and *Xho*I to release the ∼3 kb *hsp70:EWS-FLI1* fragment, which was then ligated into the 3.8 kb Tol2 transposon backbone of pT2KHG digested with *Xho*I and *Not*I (provided by Koichi Kawakami, National Institute of Genetics, Shizuoka, Japan) to create pTZ307 (*hsp70*:EWS-FLI1). To create pME-EWS-FLI1, triple-FLAG-EWS-FLI1 was PCR amplified using primers with Gateway recombination sites attB1-EF1 (5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGACTACAAGGACGACGATG-3′) and attB2-EF1 (5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCTAGTAGTAGCTGCCTAAGTGTG-3′) and recombined with pDONR221 using BP Clonase II (Invitrogen, Carlsbad, CA). To generate constructs for transposition, entry vectors p5E-bactin2 or p5E-hsp70l respectively, pME-EWS-FLI1, and p3E-IRES-EGFPpA ([@b29-0050095]) were recombined with destination vector pDESTTol2A or pDESTTol2CG2, which includes *cmlc2*:EGFP, (provided by Koichi Kawakami) in an LR reaction with LR Clonase II Plus (Invitrogen). Transposase RNA was synthesized from plasmid pCS2FA using the MMessage mMachine kit (Applied Biosystems/Ambion, Foster City, CA). Plasmids were injected at a concentration of 10--100 ng/μl with transposase RNA at 250 ng/μl.

Fixation and staining
---------------------

Fish were euthanized in Tricaine, dissected, fixed in 4% paraformaldehyde in 1× PBS for 2 days at 4°C., decalcified in 0.25 M EDTA for 4--5 days at room temperature, embedded, sagittally sectioned and stained with hematoxylin and eosin (H and E). For examination of mitotic spindles, Tg(*HSP:EWS-FLI1*) embryos were heat shocked at the 50% epiboly stage and fixed in 4% paraformaldehyde at 24 h.p.f. Anti-tubulin staining was performed as described ([@b58-0050095]). In situ hybridization was performed as described ([@b53-0050095]). Embryos were photographed and measurements of somite width and head-tail angle were performed in ImageJ.

Tumor transplants
-----------------

The tumor was removed, minced and washed in 0.9× PBS with FBS. Cells were counted and injected intraperitoneally into adult fish 2 days after irradiation (20 Gy).

RNA isolation, RT-PCR and microarray analysis
---------------------------------------------

RNA from tumors or embryos was isolated using Trizol followed by RNeasy purification (Qiagen). For leukemia-like tumors, only fixed tissue was available. The tumor-containing regions were scraped from the paraffin-embedded sections and then the RNA was purified as described above. RT-PCR for human *EWS-FLI1* was performed using primers hEWS-FLi1-R: CTAGTAGTAGCTGCCTAAGTGTG and hEWS-Fli1-Fint1: ATCCTACAGCCAAGCTCCAAGT, which are not present in the zebrafish genome. qPCR primers were resuspended at 500 nM each and validated by performing a tenfold dilution curve qPCR, starting with 2000 ng cDNA, down to 2 ng cDNA, in duplicate. RPL13a primers for reference were previously validated ([@b39-0050095]). All qPCRs were performed with three technical replicates on and Applied Biosystems 7500 Real Time PCR system using iTaq Fast SYBR green supermix with Rox from Bio-Rad (catalog no. 172--5101). Reactions were 20 μl total consisting of 2 μl primer mixes, 10 μl SYBR supermix, and 2000 ng cDNA. The Forward (F) and Reverse (R) primers used were: *sox2*, (F) GGAAACTTCTGTCCGAGAGC, (R) GGCAGGGTGTACTTGTCCTT; *nkx2.2a*, (F) CTAGATGGCTCGCAACCAC, (R) CGGACGTGTCTTGAGAGTTC; *olig2*, (F) ATGTCGATATTCCCGGTAGC, (R) CAAACACAAACACTGCACGA; *rag2*, (F) CAAACAGCTCTCAGATTTCG, (R) CCAGGTCTAGTAAGGAGAAAC; *lck*, (F) GCCTCCAGTCAGTCAGAATTT, (R) TTGTATATGGCCACCACCAG; *rpl13a*, (F) TCTGGAGGACTGTAAGAGGTATGC, (R) AGACGCACAATCTTGAGAGCAG.

For microarray experiments, MPNST samples were taken from tumors in three uninjected *tp53* mutant adults. Solid small round blue cell tumor samples were isolated from one primary tumor and transplant recipient tumor from two independent primary tumors. Total RNA (2.5 μg) from tumors was reverse-transcribed using a T7-Oligo(dT) Promoter Primer, followed by RNaseH-mediated second-strand cDNA synthesis. Biotinylated cRNA probe was prepared with MessageAmp II (Ambion), fragmented and hybridized to Affymetrix GeneChip Zebrafish Genome Arrays according to the manufacturer's protocol. Array data normalized using the RMA method and preprocessed using Chipster (Finnish IT Center for Science CSC). In accordance with the MIAME guidelines, CEL files have been deposited at the GEO repository ([@b6-0050095]), under accession number GSE31217. An empirical Bayes two groups test (*P*\<0.05, Benjamini-Hochberg corrected) was used to generate the list of 421 differentially expressed probes. Human homologs of zebrafish genes were compiled from three sources: Zebrafish Gene and Microarray Annotation Project (ZGMAP, <http://zfblast1.danio.tchlab.org/zgMap/Affymetrix.aspx>), AILUN Cross-species mapping (<http://ailun.stanford.edu/crossSpecies.php>), and Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.abcc.ncifcrf.gov/>) ([@b22-0050095]; [@b23-0050095]). Gene set enrichment analysis (GSEA, <http://www.broadinstitute.org/gsea/>) was used to compare the zebrafish EWS-FLI1 up- and downregulated genes to human microarray data ([@b51-0050095]). Analysis of overrepresented gene categories was performed using Gene Set Analysis Toolkit V2 (<http://bioinfo.vanderbilt.edu/webgestalt>).

Publicly available datasets used for gene set enrichment analysis (GSEA)
------------------------------------------------------------------------

The datasets used for GSEA are available as follows. Expression profiling of Ewing's sarcoma and rhabdomyosarcoma ([@b3-0050095]), GEO GSE967; expression profiling of human mesenchymal tumors ([@b20-0050095]), Array Express: E-MEXP-353; knockdown of EWS-FLI1 in Ewing's cell lines and expression profiling of Ewing's tumors and Bone Marrow Stem Cells ([@b54-0050095]), GEO: GSE7007. Additional BMSC samples ([@b46-0050095]), E-MEXP-215; siRNA knockdown of EWS-FLI1 in Ewing's cell lines ([@b27-0050095]), Array Express: E-GEOD-14543; knockdown of EWS-FLI1 in Ewing's cell lines ([@b48-0050095]), from <http://www.huntsmancancer.org/publicweb/content/lessnick/mscSupplementalSmith2006_files/mscSupplemental-Smith-2006.html>. Inducible Expression of EWS-FLI1 in immortalized bone marrow stromal cell line and expression profiling of Ewing's cell lines ([@b37-0050095]), GEO: GSE8665 and GSE8596. Expression profiling of Ewing's sarcoma and Neuroblastoma ([@b50-0050095]), Array Express: E-GEOD-15757.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Traditionally, cancer treatment has relied on radiation and chemotherapy, which affect both the tumor as well as normal tissue. These treatments are particularly detrimental to children and adolescents, whose developing tissues can be severely impacted, resulting in long-term side effects even when the cancer is successfully treated. Targeted therapy in which only the cancer cells are treated is the ideal solution to this problem. Cancers caused by fusion oncogenes resulting from chromosomal translocations (such as the EWS-FLI1 protein that can cause Ewing's sarcoma) are promising candidates for targeted therapies, because they contain a unique protein that is not found in healthy tissues. To date, few models have been successful in revealing the molecular function of EWS-FLI1 in cancer, which has made testing new therapies difficult. Thus, new animal models are needed to support translational studies aimed at developing targeted therapies for Ewing's sarcoma.

**Results**

The authors describe a new animal model for dissecting EWS-FLI1 function using the zebrafish *Danio rerio*. They generate the first reported lines of transgenic zebrafish expressing human EWS-FLI1. The transgenic animals exhibit two main phenotypes. First, adult fish expressing EWS-FLI1 in a subset of cells develop tumors that resemble human Ewing's sarcoma. Second, embryos that express EWS-FLI1 exhibit developmental defects, revealing specific signaling pathways that are altered in the presence of EWS-FLI1.

**Implications and future directions**

Both types of transgenic models reported here will be useful for the future study of EWS-FLI1 function. The adult zebrafish model of Ewing's sarcoma can be used in forward genetic suppressor-enhancer screens to reveal the genetic factors underlying tumor development, which might be candidates for targeted therapies. In addition, the finding that transgenic embryos have defects in convergence and extension suggests that EWS-FLI1 acts in part by suppressing non-canonical Wnt signaling, offering a candidate pathway for new therapies. Finally, because zebrafish embryos are small, transparent and develop externally, they are amenable to chemical screening. Therefore, transgenic embryos can be used in high-throughput chemical screens for drugs that inhibit the effects of EWS-FLI1. Drugs identified using such screens will be candidate therapeutics for Ewing's sarcoma.

Supplementary Material
======================
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